Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system.

Zhang, Ying; Ran, Li; Liang, Yongchao; Zhang, Yanqiu; An, Zhuoling

Zhang, Ying; Ran, Li; Liang, Yongchao; Zhang, Yanqiu; An, Zhuoling.

Affiliation

Zhang Y; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Ran L; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Liang Y; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Zhang Y; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
An Z; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Front Pharmacol ; 14: 1194545, 2023.

Article de En | MEDLINE | ID: mdl-37554985

Mots clés

Advers drug events; Food and Drug Administration adverse event reporting system; disproportionality analysis; pemigatinib; real-word study

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Front Pharmacol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google